Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Investors Back iOmx’s Focus On Tumor Immune Evasion

Developing Anti-Immune Evasion Platform

Executive Summary

The German biopharmaceutical company has been around since 2016, but now has the funding to bring its first candidate into clinical trials by late 2022

You may also be interested in...



MIG Capital: BioNTech Has Transformed Global View Of German Biotech 'But We Don’t Walk On Water’

MIG Capital’s Matthias Kromayer looks back at the huge success of its long-term backing of BioNTech and discusses the group’s next big life sciences investments, but warns that realism and hard work are needed to achieve another breakthrough.

Big Names Backers Give Altos $3bn To Pursue Cell Rejuvenation Science

Provided with a record $3bn backing from investors and bringing some big names on board, Hal Barron’s new firm Altos Labs wants to “reimagine medical treatments where reversing disease for patients of any age is possible."

Hal Barron To Depart GSK To Head Up New Biotech

As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel